C12Y 304/21111
Aqualysin 1
Official title: Aqualysin 1 (3.4.21.111)
C12Y304/21111 (Aqualysin 1) appears on 6 US grants and 12 published applications in this corpus.
Search patents in C12Y- Granted patents
- 6
- Published applications
- 12
- Assignees
- 8
- Inventors
- 45
- Latest grant
- 24 Sep 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 2 |
| 2020 | 1 | 2 |
| 2021 | 0 | 0 |
| 2022 | 2 | 0 |
| 2023 | 1 | 3 |
| 2024 | 2 | 3 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Compositions, systems, and methods for epigenetic regulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression24 Sep 2024US 12,098,399 B2Tune Therapeutics, Inc.
- Effector proteins and methods of use3 Sep 2024US 12,077,775 B2Mammoth Biosciences, Inc.
- Bakery composition11 Jul 2023US 11,696,585 B2Puratos N.V.
- Bakery composition22 Feb 2022US 11,252,969 B2Puratos N.V.
- Enzyme-inhibitor complexes comprising a thermostable hydrolase and a temperature sensitive inhibitor4 Jan 2022US 11,214,783 B2Puratos N.V.
- Programmable nuclease-peptidase compositions24 Apr 2025US 2025/0129355 A1Massachusetts Institute of Technology
- Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression5 Dec 2024US 2024/0401014 A1Tune Therapeutics, Inc.
- Effector proteins and methods of use30 May 2024US 2024/0175059 A1Mammoth Biosciences, Inc.
- Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression15 Feb 2024US 2024/0052328 A1Tune Therapeutics, Inc.
- Effector proteins and methods of use12 Oct 2023US 2023/0323406 A1Mammoth Biosciences, Inc.
Most cited
By later US patents